Vir Biotechnology (VIR) Deferred Taxes (2018 - 2024)
Vir Biotechnology (VIR) reported Deferred Taxes of -$2.6 million for Q4 2024, down 148.64% on a YoY basis from $5.4 million in Q1 2024, and down 4736.84% sequentially from $57000.0 in Q3 2024.
Vir Biotechnology (VIR) Deferred Taxes (2018 - 2024) Analysis & Trends
Vir Biotechnology (VIR) has 3 years of Deferred Taxes data on file, last reported at -$2.6 million in Q4 2024.
- For the quarter ending Q4 2024, Deferred Taxes fell 148.64% year-over-year to -$2.6 million; the trailing twelve-month figure through Dec 2024 stood at -$3.6 million (changed N/A YoY), and the FY2024 full-year result was -$2.9 million, down 177.42% from the prior year.
- Deferred Taxes eased to -$2.6 million in Q4 2024, from $57000.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $57000.0 in Q3 2024 to a low of -$2.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -188,883.60 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -65.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 96.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Vir Biotechnology | 1.38 Bn | 1.38 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.64 Mn |
| Sep 30, 2024 | 57,000.00 |
| Dec 31, 2023 | -1.06 Mn |
| Dec 31, 2018 | 980,000.00 |